Status:
ACTIVE_NOT_RECRUITING
The BALANCE Study: A Study in Spain to Find Out Whether a Patient Support Program Helps People With Pulmonary Fibrosis Who Take Nintedanib
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Pulmonary Fibrosis
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this study is to describe patients' satisfaction with Patient Support Program (Balance Program), Quality of Life and depression symptoms, dosing pattern, disease symptoms, adverse events an...
Eligibility Criteria
Inclusion
- Inclusion criteria
- Adults (≥18 years old at baseline).
- Patients included in the Patient Support Program (PSP) Balance Program.
- Ability to read and speak Spanish correctly according to the investigator criteria.
- Agree to participate and signing informed consent at baseline.
- Exclusion criteria
- \- Suspicion or diagnosis of any relevant cognitive impairment at the discretion of the investigator.
Exclusion
Key Trial Info
Start Date :
June 23 2025
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 23 2026
Estimated Enrollment :
157 Patients enrolled
Trial Details
Trial ID
NCT06912659
Start Date
June 23 2025
End Date
December 23 2026
Last Update
January 8 2026
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Evidenze Health Espana S.L.
Barcelona, Spain, 08005